Data from Immune Activity and Response Differences of Oncolytic Viral Therapy in Recurrent Glioblastoma: Gene Expression Analyses of a Phase IB Study

• DOI: 10.1158/1078-0432.c.6531350.v1
• Publication Date: 2023-04-01T06:09:16Z
• Authors: Katherine E. Miller; Kevin A. Cassady; Justin C. Roth; Jennifer Clements; Kathleen M. Schie...; Kristen Leraas; Anthony R. Miller; Nripesh Prasad; Jianmei W. Leaven...; Inmaculada B. Aban; Richard J. Whitley; G. Yancey Gillespie; Elaine R. Mardis; James M. Markert
• Keywords: Virotherapy

<div>AbstractPurpose:<p>Previously, clinical trials of experimental virotherapy for recurrent glioblastoma multiforme (GBM) demonstrated that inoculation with a conditionally replication–competent Δγ<sub>1</sub>34.5 oncolytic herpes simplex virus (oHSV), G207, was safe. Following the initial safety study, phase Ib trial enrolled 6 adult patients diagnosed GBM recurrence from which tumor tissue banked future studies.</p>Patients and Methods:<p>Here, we analyzed RNA sequencing (RNA-seq) data obtained pre- posttreatment (collected 2 or 5 days after G207 injection) biopsies study patients.</p>Results:<p>Using Spearman rank-order correlation analysis, identified approximately 500 genes whose expression pattern correlated survival duration. Many these were enriched intrinsic IFN-mediated antiviral adaptive immune functional responses, including cell chemotaxis antigen presentation to T-cells. Furthermore, show several T-cell–related highest in patient longest inoculation.</p>Conclusions:<p>Our support oHSV-induced type I IFN production subsequent recruitment an response differed between showed association duration malignant glioma treatment early generation oHSV.</p></div>